Your browser doesn't support javascript.
loading
Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement.
Kahan, Brennan C; Hall, Sophie S; Beller, Elaine M; Birchenall, Megan; Chan, An-Wen; Elbourne, Diana; Little, Paul; Fletcher, John; Golub, Robert M; Goulao, Beatriz; Hopewell, Sally; Islam, Nazrul; Zwarenstein, Merrick; Juszczak, Edmund; Montgomery, Alan A.
Afiliación
  • Kahan BC; MRC Clinical Trials Unit at UCL, London, United Kingdom.
  • Hall SS; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Beller EM; Institute for Evidence-Based Healthcare, Bond University, Queensland, Australia.
  • Birchenall M; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Chan AW; Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
  • Elbourne D; London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Little P; Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Fletcher J; The BMJ, BMA House, Tavistock Square, London, United Kingdom.
  • Golub RM; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Goulao B; Health Services Research Unit, University of Aberdeen, Aberdeen, Scotland.
  • Hopewell S; Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom.
  • Islam N; Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Zwarenstein M; The BMJ, BMA House, Tavistock Square, London, United Kingdom.
  • Juszczak E; Centre For Studies in Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Montgomery AA; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
JAMA ; 330(21): 2106-2114, 2023 12 05.
Article en En | MEDLINE | ID: mdl-38051324
ABSTRACT
Importance Transparent reporting of randomized trials is essential to facilitate critical appraisal and interpretation of results. Factorial trials, in which 2 or more interventions are assessed in the same set of participants, have unique methodological considerations. However, reporting of factorial trials is suboptimal.

Objective:

To develop a consensus-based extension to the Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement for factorial trials.

Design:

Using the Enhancing the Quality and Transparency of Health Research (EQUATOR) methodological framework, the CONSORT extension for factorial trials was developed by (1) generating a list of reporting recommendations for factorial trials using a scoping review of methodological articles identified using a MEDLINE search (from inception to May 2019) and supplemented with relevant articles from the personal collections of the authors; (2) a 3-round Delphi survey between January and June 2022 to identify additional items and assess the importance of each item, completed by 104 panelists from 14 countries; and (3) a hybrid consensus meeting attended by 15 panelists to finalize the selection and wording of items for the checklist.

Findings:

This CONSORT extension for factorial trials modifies 16 of the 37 items in the CONSORT 2010 checklist and adds 1 new item. The rationale for the importance of each item is provided. Key recommendations are (1) the reason for using a factorial design should be reported, including whether an interaction is hypothesized, (2) the treatment groups that form the main comparisons should be clearly identified, and (3) for each main comparison, the estimated interaction effect and its precision should be reported. Conclusions and Relevance This extension of the CONSORT 2010 Statement provides guidance on the reporting of factorial randomized trials and should facilitate greater understanding of and transparency in their reporting.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proyectos de Investigación / Ensayos Clínicos Controlados Aleatorios como Asunto / Revelación Límite: Humans Idioma: En Revista: JAMA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proyectos de Investigación / Ensayos Clínicos Controlados Aleatorios como Asunto / Revelación Límite: Humans Idioma: En Revista: JAMA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido